Redeye comments on FluoGuide's announcement that the first patient has been enrolled in FG001-CT-006, the company's US Phase II trial of FG001 in newly diagnosed high-grade glioma. The trial is designed to gather sufficient clinical data to support future registration of FG001. We view the enrollment as an important execution milestone that marks the company's transition from regulatory planning to clinical delivery in its lead indication.
LÄS MER
